FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to a compound of formula (1) or a pharmaceutically acceptable salt thereof, where X1 and X2 are saturated hydrocarbon groups, containing together in total from five to nine carbon atoms and zero or one oxygen atom and bonded together so that the fragment forms a monocyclic or bicyclic ring system, or where X1 and X2 are connected together so that the fragment forms , X3 and X4 are saturated hydrocarbon groups, containing in total from three to six carbon atoms and bonded together in such a way that the fragment forms a monocyclic or bicyclic ring system, R1 is selected from NR5R6, CONR5R6, COOR7, 5- or 6-member ring containing 0, 1 or 2 heteroatoms selected from N, which is optionally substituted with C1-C3 alkyl, CONR5R6, halogen, oxo, CH2OH or pyrazole ring substituted with C1-C3 alkyl, or R1 is bonded to R2 to form a monocyclic or bicyclic ring containing 1 or 2 heteroatoms selected from O and N, which is substituted with one or more substitutes selected from C1-C6 alkyl and oxo, R2 is selected from hydrogen and cyano, R4 is a C1-6 alkyl group, optionally substituted with one or more fluorine atoms, R5 is selected from COCH3, a non-aromatic C1-10 saturated hydrocarbon group, optionally substituted with one or more fluorine atoms, R6 is selected from hydrogen and non-aromatic C1-10 saturated hydrocarbon group and R7 is a non-aromatic C1-6 saturated hydrocarbon group. Invention also relates to a pharmaceutical composition having M1 and/or M4 muscarinic receptor agonist activity based on the compound of formula (1).
EFFECT: obtaining novel compounds and a pharmaceutical composition based on them, which can be used in medicine in treating diseases mediated by muscarinic receptors M1 and / or M4, such as Alzheimer's disease, Lewy body dementia, pain.
23 cl, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOUNDS | 2018 |
|
RU2767857C2 |
SPIRO-FUSED PIPERIDINE DERIVATIVES FOR APPLICATION AS INHIBITORS OF EXTERNAL MEDULLAR LAYER POTASSIUM CHANNEL | 2013 |
|
RU2642066C2 |
1,6-DIAZABICYCLO[3,2,1]OCTAN-7-ONА DERIVATIVES AND USING THEM IN TREATING BACTERIAL INFECTIONS | 2012 |
|
RU2570423C2 |
PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS FOR APPLICATION | 2012 |
|
RU2638552C2 |
DIPEPTIDYL PEPTIDASE-IV INHIBITORS | 2010 |
|
RU2574410C2 |
MUSCARINIC RECEPTOR AGONISTS | 2015 |
|
RU2678835C2 |
NEW BIPHENYL COMPOUND OR ITS SALT | 2018 |
|
RU2765152C2 |
METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF AN LSD 1INHIBITOR BASED ON THE INSM1 EXPRESSION | 2018 |
|
RU2789449C2 |
SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | 2012 |
|
RU2621695C2 |
6-(PYRIMIDINOAMINO-PYRIDINE)BENZOIMIDAZOLE DERIVATIVES, USEFUL FOR TREATMENT OF CANCER | 2014 |
|
RU2670762C2 |
Authors
Dates
2024-04-09—Published
2019-06-24—Filed